Tema Etfs LLC Reduces Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR
Tema Etfs LLC significantly reduced its stake in Arrowhead Pharmaceuticals by 63.7% in Q4, selling over 20,000 shares. Despite this, analysts maintain a "Moderate Buy" rating with a consensus price target of $81.67, and institutional investors still own a substantial portion of the company's stock. Insider selling by COO Patrick O'Brien and James C. Hamilton also occurred, totaling over $6 million in sales.
Arrowhead Pharmaceuticals Leads with 415.53% Return in Stock Performance
Arrowhead Pharmaceuticals has demonstrated exceptional stock performance over the past year, leading with an impressive 415.53% return in the Pharmaceuticals & Biotechnology sector. Other top performers include Seagate Technology (IT - Hardware), TTM Technologies (Electronics), ViaSat (Telecom), and Comfort Systems USA (Construction), all showing significant returns. These companies highlight promising growth opportunities across diverse market sectors, attracting considerable investor interest.
Arrowhead Pharmaceuticals, Inc. (ARWR) Jumps 7.3% to $61.87
Arrowhead Pharmaceuticals (ARWR) saw its stock jump 7.3% to $61.87 on Tuesday, participating in a broad rally of biotechnology stocks. This surge, which involved several other sector peers, suggests a shift in investor sentiment towards the biotech industry rather than company-specific news for Arrowhead. Investors are advised to monitor whether this sector-wide momentum continues.
Arrowhead Pharmaceuticals, Inc. (ARWR) Jumps 7.3% to $61.87
Arrowhead Pharmaceuticals (ARWR) saw its stock price jump 7.3% to $61.87 on Tuesday, participating in a broad rally across the biotechnology sector. This $8.7 billion company's rise, alongside others like PRAX and NUVL, suggests a sector-wide bullish sentiment rather than specific company news. Investors are advised to monitor whether this sector momentum continues, as future price drivers for Arrowhead will likely be company-specific clinical trial updates.
Arrowhead Pharmaceuticals (ARWR) price target increased by 17.24% to 59.24
Arrowhead Pharmaceuticals (ARWR) recently saw its price target increased by 17.24% to a new target of $59.24. This adjustment reflects an updated valuation or outlook for the company's stock. Investors and market watchers will likely consider this revised target in their analysis of ARWR.
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo
Arrowhead Pharmaceuticals announced long-term efficacy and safety data for plozasiran in patients with hypertriglyceridemia (HTG), showing significant and durable reductions in triglycerides, with 96% of severe HTG patients achieving levels below 500 mg/dL. The data, presented at ACC.26 and published in the American Journal of Preventive Cardiology, demonstrated a favorable safety profile and no adjudicated acute pancreatitis events over a two-year period. The company plans to submit a supplemental New Drug Application to the U.S. FDA by year-end 2026 for plozasiran in severe HTG.
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo
Arrowhead Pharmaceuticals announced long-term efficacy and safety data for plozasiran from a two-year open-label extension study. The data, presented at the ACC.26, showed significant and durable reductions in triglycerides and atherogenic lipoproteins across various hypertriglyceridemia patient populations, with a consistent safety profile and no adjudicated acute pancreatitis events. This reinforced APOC3 silencing as a central mechanism in triglyceride clearance.
How Investors May Respond To Arrowhead Pharmaceuticals (ARWR) Plozasiran’s Two-Year Triglyceride and Safety Data
Arrowhead Pharmaceuticals released two-year open-label extension data for its investigational drug plozasiran, showing durable triglyceride reductions and a consistent safety profile in patients with severe hypertriglyceridemia, with no reported acute pancreatitis events. This positive data strengthens plozasiran's clinical profile and supports Arrowhead's potential transition towards a product-based revenue model. Investors are now evaluating how these long-term safety and efficacy signals will influence the company's investment narrative, especially considering upcoming Phase 3 readouts and regulatory milestones, as well as the varying analyst forecasts for future revenue.
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo
Arrowhead Pharmaceuticals announced encouraging long-term efficacy and safety data for plozasiran in patients with hypertriglyceridemia (HTG), including severe hypertriglyceridemia (sHTG). The two-year open-label extension study showed significant reductions in triglycerides and atherogenic lipoproteins, with a favorable safety profile and no adjudicated acute pancreatitis events. These findings support plozasiran's potential as a therapeutic solution and the company plans to submit a supplemental New Drug Application (sNDA) to the U.S. FDA by year-end 2026.
Arrowhead Pharmaceuticals Presents Long-Term Data on Plozasiran Showing Consistent Triglyceride Reductions in Hypertriglyceridemia
Arrowhead Pharmaceuticals presented new long-term efficacy and safety data for its investigational RNA interference therapeutic, Plozasiran, at the American College of Cardiology’s 75th Annual Scientific Session and Expo. The data highlighted consistent reductions in triglyceride levels across various hypertriglyceridemia conditions and patient groups, demonstrating sustained efficacy and a monitored safety profile. These findings are part of ongoing research to address cardiovascular risks associated with high triglyceride levels.
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo
Arrowhead Pharmaceuticals announced long-term efficacy and safety data for its investigational drug plozasiran, showing significant reductions in triglycerides (TG) and atherogenic lipoproteins in patients with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (sHTG). The two-year open-label extension study found that sHTG patients achieved an 83% median reduction in TG, with 96% reaching levels below 500 mg/dL, and no adjudicated acute pancreatitis events occurred. These promising results reinforce plozasiran's potential as a durable therapeutic solution, with global Phase 3 clinical studies for marketing approval expected to conclude in mid-2026.
BofA Securities Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Cuts Target Price to $81
BofA Securities has reiterated its Buy rating for Arrowhead Pharmaceuticals (ARWR.US) but has lowered its price target for the company to $81. This adjustment suggests a continued positive outlook on the stock's potential, despite a revised valuation by the analyst.
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Strong One Year Shareholder Return
Arrowhead Pharmaceuticals (ARWR) has seen a significant share price increase of 336% over the past year, despite recent short-term declines. The stock is currently trading slightly below analyst targets and intrinsic value estimates, with a fair value pegged at around $64.08 per share. While the company's RNAi delivery technology and pipeline breadth suggest strong future potential, its high P/E ratio compared to the industry average raises questions about whether its valuation is justified or overly optimistic.
Vanguard amendment shows 0% holding in Arrowhead (ARWR)
Vanguard has filed an amendment (SCHEDULE 13G/A) reporting a 0% beneficial ownership in Arrowhead Pharmaceuticals (ARWR). This change is due to an internal realignment on January 12, 2026, where certain Vanguard subsidiaries will now report their holdings separately, in accordance with SEC Release No. 34-39538. The filing explicitly states 0 shares beneficially owned by The Vanguard Group.
Arrowhead Pharma stock rating reiterated at Buy by TD Cowen
TD Cowen has reiterated a Buy rating on Arrowhead Pharmaceuticals (NASDAQ:ARWR) following discussions on its obesity and metabolic disease programs. The firm suggests that the primary role for the company's INHBE and ALK7 mechanisms will likely be in adjunctive and maintenance settings or targeted indications such as Type 2 diabetes and MASH. This comes as the stock has surged 336% over the past year, despite recent analyst adjustments to price targets due to competitor data and ongoing trials.
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Strong One Year Shareholder Return
Arrowhead Pharmaceuticals (ARWR) has seen a recent share price jump, bringing its one-year total shareholder return to 336%, despite some recent short-term declines. The company's valuation narrative suggests it is about 5.2% undervalued, with a fair value of $64.08 per share, supported by its RNAi delivery technology and pipeline breadth. However, its P/E ratio of 42.1x is significantly higher than the industry average, prompting questions about whether this reflects genuine quality or overstretched expectations.
Arrowhead Pharmaceuticals Surges as Clinical Trial Doses First Patients
Arrowhead Pharmaceuticals (ARWR) saw its stock surge over 8% after announcing promising phase 2 clinical results and FDA designations. The company has also begun dosing patients in a Phase 1/2a trial for ARO-DIMER-PA, focusing on dual gene silencing for atherosclerotic cardiovascular disease, signaling potential market disruptions and a strategic shift in its RNAi-based therapeutic developments. Investors are closely watching these clinical advancements and upcoming investor conferences to gauge the company's future growth.
Arrowhead Pharma (ARWR) Rating Reiterated as 'Buy' by HC Wainwri
HC Wainwright & Co. analyst Patrick R. Trucchio has reiterated a 'Buy' rating for Arrowhead Pharma (ARWR) with a stable price target of $100.00. This follows previous positive ratings from HC Wainwright and other firms like B. Riley Securities, Piper Sandler, and Chardan Capital, which have recently raised their price targets for the biotechnology company. Arrowhead Pharmaceuticals focuses on developing medicines for genetically-driven diseases, particularly those involving protein overproduction, with a portfolio addressing various conditions including cardiovascular and liver diseases.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Up 8.6% - Here's What Happened
Arrowhead Pharmaceuticals (NASDAQ:ARWR) stock price increased by 8.6% on Wednesday, trading at $61.12 on significantly lower volume. Analysts are largely bullish on the company, with a "Moderate Buy" consensus and an average price target of $81.67, despite the last quarter showing mixed results with an EPS miss but a revenue beat. Insider selling of approximately 172,100 shares worth $11.3 million was also reported during the quarter.
Assenagon Asset Management S.A. Purchases 304,264 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR
Assenagon Asset Management S.A. significantly increased its holdings in Arrowhead Pharmaceuticals, acquiring an additional 304,264 shares, bringing its total to 684,889 shares valued at approximately $45.47 million. Despite recent insider selling, which saw executives offloading shares, analysts maintain a "Moderate Buy" consensus for ARWR, with an average price target of $81.67. The biotechnology company, focused on RNA interference therapeutics, recently reported strong quarterly revenue growth, though it missed EPS estimates.
JPMorgan Chase & Co. Grows Stake in Arrowhead Pharmaceuticals, Inc. $ARWR
JPMorgan Chase & Co. significantly increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 90.3% in Q3, now owning 775,717 shares valued at $26.75 million. This comes despite Arrowhead missing EPS expectations but surpassing revenue forecasts with substantial year-over-year growth in its latest quarter. While institutional investors are increasing their positions, company insiders have been net sellers, offloading shares totaling over $11 million in the last 90 days.
Arrowhead Shareholders Reject Say-on-Pay at 2026 Meeting
Arrowhead Pharmaceuticals (ARWR) shareholders rejected the advisory Say-on-Pay proposal at their 2026 Annual Meeting, indicating dissatisfaction with executive compensation despite approving other proposals like director elections and an incentive plan. The company's board and management may need to reevaluate pay structures and enhance engagement with investors following this vote. TipRanks' AI Analyst, Spark, rates ARWR as "Neutral," citing improved financial performance but concerns about high valuation without dividend support.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) holders back board but reject Say-on-Pay
Arrowhead Pharmaceuticals' stockholders elected seven directors and approved the Amended and Restated 2021 Incentive Plan and KPMG LLP as auditors at their 2026 annual meeting. However, they rejected the advisory Say-on-Pay proposal, signaling dissatisfaction with executive compensation. This outcome indicates shareholder support for the board's composition and equity framework but concerns regarding executive pay.
Arrowhead’s bid to become a large-cap biotech
Arrowhead Pharmaceuticals is embarking on its first commercial launch after two decades of platform development and strategic shifts. The company believes its current pipeline and enabling technologies, including Redemplo, cardiometabolic breadth, and extrahepatic delivery, will drive significant value creation and elevate it to a large-cap biotech. This growth phase follows extensive refinement of its RNAi-focused platform to enhance its clinical and commercial competitiveness.
A Look At Arrowhead Pharmaceuticals (ARWR) Valuation As Fisher Builds Stake And SHASTA Readouts Approach
Arrowhead Pharmaceuticals (ARWR) is gaining attention as Ken Fisher's fund increases its stake and the company anticipates Phase III SHASTA-3 and SHASTA-4 readouts for plozasiran, a potential multi-billion dollar opportunity. While the stock shows a 61% intrinsic value gap and a discount to analyst targets, its current P/E ratio of 39.3x is significantly higher than industry averages, suggesting valuation risk. Investors are weighing long-term momentum against recent cautious sentiment as these key clinical trial results approach.
Arrowhead Pharmaceuticals (ARWR) price target increased by 17.24% to 59.24
This article reports that the price target for Arrowhead Pharmaceuticals (ARWR) has been increased by 17.24%, setting the new target at $59.24. This adjustment could reflect updated analyst expectations or recent developments concerning the company. Investors may view this as a positive sign for the stock's future performance.
A Look At Arrowhead Pharmaceuticals (ARWR) Valuation As Fisher Builds Stake And SHASTA Readouts Approach
Arrowhead Pharmaceuticals (ARWR) is gaining attention as Ken Fisher's fund increases its stake and key Phase III SHASTA readouts for plozasiran, a potential multibillion-dollar drug, approach. Despite recent stock declines, the company shows strong long-term momentum and analysts suggest it is undervalued, with a fair value estimate of $64.08 compared to its current price of $56.71. However, its high P/E ratio signals valuation risk if future expectations are not met.
Arrowhead Pharmaceuticals (ARWR) Is Down 5.4% After First Drug REDEMPLO Wins FDA Approval - What's Changed
Arrowhead Pharmaceuticals' stock dropped 5.4% despite its first drug, REDEMPLO, receiving FDA approval, alongside clearances in China and Canada. This approval transitions Arrowhead into a commercial-stage company, impacting its revenue mix, risk profile, and reliance on partnerships. The company reported strong Q1 FY2026 results, but investors are advised to consider diverging analyst opinions on its future revenue and profitability, especially given cautious forecasts regarding pricing pressure and competition.
10 Health Care Stocks Whale Activity In Today's Session
This article identifies significant "whale activity" in the options market for ten healthcare stocks, including Hims & Hers Health, Johnson & Johnson, and Eli Lilly. It details specific large-volume options trades, categorized by sentiment (bullish, bearish, neutral), strike price, expiration date, and total trade cost. The article aims to inform traders about potentially impactful options movements in the healthcare sector.
Arrowhead Pharmaceuticals Inc. (ARWR): Billionaire Ken Fisher Bets Big on Pharma
Billionaire Ken Fisher's Fisher Asset Management has significantly increased its stake in Arrowhead Pharmaceuticals Inc. (ARWR) despite Fisher's usual caution regarding biotech investments. The fund aggressively added to its initial Q2 2024 stake through late 2024 and early 2025, with a recent 25% increase. This interest likely stems from Arrowhead's recent strong earnings and its promising drug pipeline, including plozasiran which has a potential commercial opportunity of $3 billion to $4 billion.
Arrowhead (ARWR) FQ1 2026 revenue hits $264M as REDEMPLO approval marks commercial shift
Arrowhead Pharmaceuticals reported Q1 2026 revenue of $264 million, primarily driven by a significant milestone payment for the approval of REDEMPLO. This approval marks a pivotal shift for the company towards commercial operations and validates its RNAi therapeutic platform, with a planned launch in the second half of 2026.
Arrowhead Pharmaceuticals (ARWR) Is Down 5.4% After First Drug REDEMPLO Wins FDA Approval - What's Changed
Arrowhead Pharmaceuticals' stock dropped 5.4% despite its first drug, REDEMPLO, receiving FDA approval for familial chylomicronemia syndrome. This approval marks a shift for the company from an R&D focus to a commercial stage, potentially altering its revenue mix and risk profile. While recent strong Q1 FY2026 results show profitability driven by collaboration and early sales, the long-term success hinges on REDEMPLO's ability to generate recurring revenue to offset rising operating expenses.
How Arrowhead Pharmaceuticals Inc. (ARWR) Affects Rotational Strategy Timing
Arrowhead Pharmaceuticals Inc. (ARWR) is showing weak near and mid-term sentiment but a strong long-term outlook, with support currently being tested. AI models have generated three trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels. The analysis highlights an exceptional 64.9:1 risk-reward setup for a potential 19.3% gain.
Baker BROS. Advisors LP Purchases 731,588 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR
Baker BROS. Advisors LP significantly increased its stake in Arrowhead Pharmaceuticals, Inc. by purchasing 731,588 additional shares, bringing their total to over 1.67 million shares. This move makes Arrowhead Pharmaceuticals the 25th largest position in Baker BROS.'s portfolio. The article also details other hedge fund activities, stock performance metrics, insider trades, and recent analyst ratings for ARWR.
Avoro Capital Advisors LLC Has $375.94 Million Position in Arrowhead Pharmaceuticals, Inc. $ARWR
Avoro Capital Advisors LLC significantly increased its stake in Arrowhead Pharmaceuticals (NASDAQ:ARWR) by 2.8% in Q3, now owning 10.9 million shares valued at $375.94 million, making it their 6th largest holding. Despite a recent earnings per share miss, Wall Street analysts maintain a "Moderate Buy" rating with a consensus price target of $81.67, even as company insiders have sold a substantial amount of shares. The company specializes in RNA interference therapeutics and reported a significant revenue increase year-over-year.
225,000 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Bought by Integral Health Asset Management LLC
Integral Health Asset Management LLC recently acquired 225,000 shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) valued at approximately $7.76 million during the third quarter. This acquisition comes as company insiders have been net sellers, offloading over 495,000 shares. Arrowhead Pharmaceuticals exceeded revenue expectations but missed its EPS target in its latest quarterly earnings report.
Arrowhead (ARWR) FQ1 2026 Revenue Hits $264M as REDEMPLO Approval Marks Commercial Shift
Arrowhead Pharmaceuticals Inc. (ARWR) achieved a significant milestone in FQ1 2026, transitioning to a commercial-stage company following the US FDA approval of its first medicine, REDEMPLO (plozasiran). The company reported a net income of $30.8 million, a stark improvement from the previous year's loss, driven by $264 million in revenue, which included upfront payments and milestone achievements. Arrowhead is also advancing its R&D pipeline with new clinical trials and promising interim data in obesity programs.
Arrowhead (NASDAQ: ARWR) CMO sells 10,000 shares in planned Form 4 trade
Arrowhead Pharmaceuticals' Chief Medical Officer, James C. Hamilton, sold 10,000 shares of common stock at a weighted average price of $64.19 per share on March 5, 2026. This transaction was conducted under a Rule 10b5-1 trading plan. Following the sale, Hamilton directly owns 236,958 shares, including restricted stock units subject to vesting.
Arrowhead Pharmaceuticals CMO Sells 10,000 Shares
Arrowhead Pharmaceuticals' Chief Medical Officer, James C Hamilton, sold 10,000 shares of common stock for a total of $641,900 on March 5, 2026. The transaction was conducted under a 10b5-1 trading plan, leaving Hamilton with 236,958 direct shares in the company.
Arrowhead (ARWR): Do Strong Q1 Results and Plozasiran Hopes Outweigh Insider Selling Signals?
Arrowhead Pharmaceuticals recently exceeded Q1 fiscal 2026 earnings and revenue expectations, while its Chief Medical Officer sold 10,000 shares under a 10b5-1 plan. Investors are focused on the upcoming Phase 3 plozasiran SHASTA3/4 trial as a key catalyst. The company's investment narrative balances strong financial results and pipeline potential against a premium valuation, high R&D spend, and potential insider selling signals.
Arrowhead (ARWR): Do Strong Q1 Results and Plozasiran Hopes Outweigh Insider Selling Signals?
Arrowhead Pharmaceuticals reported strong Q1 fiscal 2026 results, exceeding revenue and earnings expectations, coinciding with its CMO's sale of 10,000 shares under a 10b5-1 plan. Investors are closely watching the Phase 3 plozasiran SHASTA3/4 trial as a key catalyst. Despite the positive earnings, the article highlights the importance of the company's RNAi platform and late-stage programs in justifying its valuation and the potential impact of rising commercialization costs on future capital needs.
Arrowhead Pharmaceuticals Teases Q3 Data Wave: SHASTA-3/4, RNAi Dimer and ARO-MAPT Readouts Ahead
Arrowhead Pharmaceuticals announced upcoming clinical data readouts concentrated in Q3 2026, including topline results for SHASTA-3 and SHASTA-4 for plozasiran in SHTG, initial data from its RNAi dimer program for mixed hyperlipidemia, and CSF tau data from ARO-MAPT for CNS targets. The company also plans updates in H2 2026 for its obesity programs, ARO-ALK7 and ARO-INHBE, highlighting early positive signals including fat redistribution and liver fat reduction. Arrowhead is also focusing on commercializing its approved familial chylomicronemia syndrome (FCS) treatment and preparing for a supplemental NDA filing for SHTG in Q4.
Arrowhead (ARWR): Do Strong Q1 Results and Plozasiran Hopes Outweigh Insider Selling Signals?
Arrowhead Pharmaceuticals reported strong Q1 fiscal 2026 results, surpassing revenue and earnings expectations, while its Chief Medical Officer sold 10,000 shares under a 10b5-1 plan. Investors are focused on the upcoming Phase 3 plozasiran SHASTA3/4 trial as a significant catalyst. The article suggests that despite the strong quarter, rising costs for commercialization and Phase 3 trials could necessitate future capital raises.
Hamilton James, Arrowhead Pharmaceuticals CMO, sells $641,900 in stock
Hamilton James C., Chief Medical Officer of Arrowhead Pharmaceuticals (NASDAQ:ARWR), sold 10,000 shares of company stock for $641,900 on March 5, 2026, under a pre-arranged trading plan. Despite recent strong Q1 2026 financial results exceeding expectations, the stock is considered overvalued by InvestingPro. Goldman Sachs maintains a Neutral rating with an $85 price target, highlighting the company's transition to a commercial stage and upcoming trial results as potential catalysts.
Hamilton James, Arrowhead Pharmaceuticals CMO, sells $641,900 in stock
Hamilton James C., Chief Medical Officer of Arrowhead Pharmaceuticals (NASDAQ:ARWR), sold 10,000 shares of company stock for $641,900 on March 5, 2026, under a pre-arranged trading plan. Despite the stock's 257% return over the past year, InvestingPro analysis suggests it may be overvalued. This transaction follows strong Q1 fiscal year 2026 financial results where the company surpassed earnings and revenue expectations, though future earnings guidance has caused a stock decline.
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Citigroup Inc.
Citigroup Inc. significantly reduced its stake in Arrowhead Pharmaceuticals (NASDAQ:ARWR) by 63.4%, selling over 89,000 shares. Despite this, other institutional investors have increased their positions, and analysts maintain a "Moderate Buy" rating with a consensus price target of $81.67, following recent target raises from major banks. The company also reported mixed Q3 earnings, missing EPS estimates but exceeding revenue expectations with substantial year-over-year growth.
ARWR SEC Filings - Arrowhead Pharma 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors to access Arrowhead Pharma's (ARWR) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material event reports (8-K), and insider trading forms. It highlights key developments from these filings, such as FDA approvals for REDEMPLO, clinical trial advancements, collaboration agreements with major pharmaceutical companies, and capital markets transactions. The platform also offers AI-powered summaries and specialized views to help users understand complex financial documents and track insider disclosures.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Insider James Hamilton Sells 10,000 Shares
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director James Hamilton sold 10,000 shares of the company's stock on March 5th, totaling $641,900. This sale reduced his stake by 4.05% to 236,958 shares, valued at approximately $15.21 million. The company recently reported quarterly results that missed EPS estimates but exceeded revenue expectations, with a significant year-over-year revenue increase.
Piper Sandler maintains an overweight rating on Arrowhead Pharmaceuticals, Inc. (ARWR)
Piper Sandler has reiterated an overweight rating for Arrowhead Pharmaceuticals, Inc. (ARWR). This indicates the firm's positive outlook on the company's stock performance. The article does not provide further details on the reasons behind this rating.
Rafferty Asset Management LLC Sells 27,546 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR
Rafferty Asset Management LLC reduced its stake in Arrowhead Pharmaceuticals (NASDAQ:ARWR) by 19.4% in the third quarter, selling 27,546 shares and now holding 114,379 shares valued at approximately $3.95 million. Despite institutional selling, analysts have a "Moderate Buy" consensus rating for ARWR with a target price of $81.67, following a quarter where the company missed EPS estimates but significantly beat revenue expectations, reporting $264.0 million. Company insiders have also sold a substantial amount of shares totaling over $33 million in the past three months.
